Anticoagulation therapy in patients with paroxysmal atrial fibrillation;Antikoagulasjonsbehandling ved forbigående atrieflimmer

Tidsskrift for den Norske Laegeforening

Volumn 124, Issue 7, 2004, Pages 950-952

  Risøe, Cecilie ^a   Gjesdal, Knut ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

AGE; ANTICOAGULANT THERAPY; BRAIN INFARCTION; CARDIOVASCULAR RISK; DIABETES MELLITUS; ELECTROSTIMULATION THERAPY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; PATIENT INFORMATION; PRACTICE GUIDELINE; REVIEW; THROMBOEMBOLISM;

EID: 1842734476     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Gjesdal K. Antikoaguiasjonsbehandling ved atrieflimmer. Tidsskr Nor Lægeforen 2002; 122: 191-2.
2. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL et al. ACC/AHN/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001; 22: 1852-923.
3. Gallagher MM, Camm AJ. Schemes of classification. Replace a number of complicated systems with a simple division of atrial fibrillation (AF) based on temporal pattern. Pacing Clin Electrophysiol 1998; 21: 776-7.
4. Ostrander LD jr., Brandt RJ, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 1965; 31: 888-98.
5. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; 1: 526-9.
6. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the cardiovascular health study). Am J Cardiol 1994; 74: 236-41.
7. Wolf P, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke. The Framingham study. Stroke 1991; 22: 983-8.
8. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM et al. The natural history of lone atrial fibrillation. A population based study over three decades. N Engl J Med 1987; 317: 669-74.
9. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30 years follow-up in the Framingham study. JAMA 1985; 254:3449-53.
10. Wolf PA, Dawber TR, Thomas HE jr., Kannel WB. Epidemiologic assessment of atrial fibrillation and risk of stroke: The Framingham study. Neurology 1978; 28: 973-7.
11. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett ELC. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-7.
12. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
13. Petersen P, Madsen EB, Brun B, Pedersen F, Gyldensted C, Boysen G. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987; 18: 1098-100.
14. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrilation: incidence and predictors during asperin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35: 183-7.
15. Brandes A, Chen X, Gadsbøll N, Hansen PS, Petersen HH, Pehrson S et al. Behandling af atrieflimmer og atrieflagren. Cardiologisk Forum 2003; nr. 2: 31-53.
16. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989; 13: 617-23.
17. Stoddard MF, Dawkins P, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995; 129: 1204-15.
18. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of acute atrial fibrillation: evidence for «stunning» as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23: 307-16.
19. Grimm RA, Leung DY, Black IW, Stewart WJ, Thomas JD, Klein AL. Left atrial appendage «stunning» after spontaneous cardioversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J 1995; 130: 174-6.
20. Terapianbefalinger: behandling av atrieflimmer. Nytt om legemidler 1996; 19 (suppl 5): 2-30.
21. Terapianbefaling: Antitrombotisk og fibrinolytisk behandling i kardiologi. Oslo: Statens legemiddel-kontroll, 2000.
22. Chung MK. Atrial fibrillation: Rate control is as good as rhythm control for some, but not all. Cleve Clin J Med 2003; 70: 569-73.
23. The Atrial Fibrillation Investigators. The efficacy of asperin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. Arch Intern Med 1997; 157: 1237-40.
24. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with asperin. Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279:1273-7.
25. Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-43.
26. Glotzer TV, Hellkamp AS, Zimmermann J, Sweeney MO, Yee R, Marinchak R et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke. Report of the atrial diagnostics ancillary study of the Mode Selection Trial (MOST). Circulation 2003; 107: 1614-9.
27. Executive Steering Committee on behalf of the SPORTIF III investigators. Stroke prevention with the oral thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362: 1691-8.